142 related articles for article (PubMed ID: 17106870)
1. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea.
Narath R; Ambros IM; Kowalska A; Bozsaky E; Boukamp P; Ambros PF
Genes Chromosomes Cancer; 2007 Feb; 46(2):130-42. PubMed ID: 17106870
[TBL] [Abstract][Full Text] [Related]
2. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
3. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
5. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
6. The MYCN enigma: significance of MYCN expression in neuroblastoma.
Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
[TBL] [Abstract][Full Text] [Related]
7. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
8. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
10. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
11. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
13. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
[TBL] [Abstract][Full Text] [Related]
14. Concomitant DDX1 and MYCN gain in neuroblastoma.
Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
[TBL] [Abstract][Full Text] [Related]
15. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine.
Prochazka P; Hrabeta J; Vícha A; Eckschlager T
Cancer Genet Cytogenet; 2010 Jan; 196(1):96-104. PubMed ID: 19963143
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation--sign of tumour cell revertance?
Ambros IM; Rumpler S; Luegmayr A; Hattinger CM; Strehl S; Kovar H; Gadner H; Ambros PF
Eur J Cancer; 1997 Oct; 33(12):2043-9. PubMed ID: 9516850
[TBL] [Abstract][Full Text] [Related]
17. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
18. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
20. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
